Skip to content

The Effect of Duralabhadi Avaleha in the managemnet of Bronchial ASthma in children.

Efficacy of Duralabhadi Avaleha in comparison to Vasa Avaleha in the management of Childhood Tamaka Shawa Bronchila Asthma An open label randomized clinical Trial. - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101312
Enrollment
204
Registered
2026-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

None listed

Sponsors

Dr Mukesh Kumar Meena
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1Patient presenting with 03 Cardinal symptoms of Tamka shawasa Dyspnoea, Rhonchi, Difficult expectoration and at least two symptoms of Cough, Chest pain, Insomnia, Nasal discharge. 2Patients having C-ACT score of less than 19. 3Patients with mild to moderate bronchial asthma with at least three asthma episodes during last year. 4Provided a signed statement of informed LAR consent assent from the parent guardian and child adolescent.

Exclusion criteria

Exclusion criteria: 1Patients below 6 years and above 12 years of age. 2Patients with severe bronchial asthma with prolonged remissions lasting more than a month. 3Severe and Complicated respiratory allergic disorders those need hospitalization. 4Patients associated with case of Tuberculosis, Pleural effusion, Emphysema, Lung abscess, Bronchiectasis, Pleurisy, Nasal polyps, Congenital lung cardiac anomalies, Chronic debilitating diseases 5Individuals with significant cardiovascular conditions, additional infectious ailments, and clinically significant disorders affecting the cardiovascular, renal, hepatic, neurological, haematological, endocrine, or respiratory systems, excluding asthma, are included. 6Patients who will not be willing to comply with protocol requirements will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Improvement in clinical sign and symptoms of Tamaka Shwasa in terms of reduction in frequency, duration and severity of attacks.Timepoint: Base line,45th day and 90th day

Secondary

MeasureTime frame
1.Improvement in Paediatric Asthma Quality of Life Questionnaire. 2.Improvement in asthma control as per CACT. 3.Changes in laboratory parameters Complete hemogram DLC TLC Hb ESR Absolute Eosinophil count Serum IgE 4 Improvement in Pulmonary Function Test by Spirometry FEV Forced expiratory volume FVC Forced vital capacity PEFR Peak expiratory flow rate 5.Reduction in FeNO level Pulmonary inflammation 6.Improvement in Pulmonary Function Test by FOT Forced oscillation technique. FeNO & FOT tests will be considered for investigation if feasible as both are relatively costly & the necessary facilities are currently unavailable at A & U Tibbia College & Hospital. Timepoint: Base line, 45th day

Countries

India

Contacts

Public ContactDr Mahapatra Arun Kumar

All India Institute Of Ayurveda New Delhi

ayuarun@gmail.com8506821947

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026